UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC
Emily Miller Ray , Paula D. Strassle , Charles E. Gaber , Hyman B. Muss , Stephanie M. Downs-Canner
Background: Omission of axillary surgery is appropriate in some patients with clinically node-negative (cN0), HR+ ESBC; however, there are no pre-operative tools to predict pathologic node positivity (pN+) in these women. We propose a clinically validated predictive model to inform treatment decisions regarding axillary evaluation. Methods: We constructed a cohort of adult women with ESBC (clinical T1/T2, N0, M0) diagnosed 2012-2016, who underwent lumpectomy or mastectomy and lymph node surgery without neoadjuvant therapy using the National Cancer Database breast cancer dataset. The dataset was non-randomly split into training (2012-2015) and testing (2016) for development and validation. Stepwise logistic regression was used to identify predictors of pathologic node positivity (pN0 vs pN+) in the training dataset. Potential predictors included: age, race, ethnicity, comorbidity score, histologic type, clinical T, ER positivity, PR positivity, HER2 positivity, and grade. Predictor variables required a bivariate p-value <0.30 to be entered into model, and an adjusted p-value <0.35 to stay in model. A partial score method was used to develop a lymph node prediction score (LNPS) by assigning a weighted value to each strong predictor variable (OR >1.5) and adding together the values for each included variable. LNPS was treated as a linear variable for prediction in validation dataset. Results: 423,068 women were included (2012-2015: 334,778; 2016: 88,290). Pathologic node positivity was 17% in 2012-2015 and 2016. All variables were included in the final stepwise model. Strong predictors were age, histologic type, clinical T, and grade. Scores ranged from 0-11. In the validation dataset, predicted pN+ by LNPS was very similar to actual pN+ (Table). A 1-point increase in LNPS was associated with a 3.3% increase in absolute risk of pN+. Conclusions: A novel lymph node prediction score can be used in HR+ cT1-T2 cN0 breast cancers to estimate the probability of pN+ and guide decisions regarding axillary surgical evaluation.
LNPSa | N | Predicted pN+ (%) | Actual pN+ (%) | Difference (%) |
---|---|---|---|---|
0 | 1,507 | 6.5 | 3.2 | 3.3 |
1 | 871 | 7.9 | 5.0 | 2.9 |
2 | 128 | 9.6 | 7.8 | 1.8 |
4 | 30,217 | 14.1 | 14.9 | -0.8 |
6 | 1,381 | 20.2 | 18.2 | 2.0 |
8 | 4,194 | 28.0 | 31.2 | -3.2 |
10 | 3,722 | 37.4 | 32.9 | 4.5 |
11 | 78 | 42.6 | 46.2 | -3.6 |
aLNPS included: age (18-59 years: 1 point; ≥60 years: 0), histologic type (lobular: 4; ductal: 3, other subtypes: 0), clinical T (T1mi/T1a: 0; T1b: 1; T1c: 3; T2: 7; T1 unspecified: 2), and grade (grade I/II: 0; grade III/IV: 1)
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2023 ASCO Annual Meeting
First Author: Yi Lee
2023 ASCO Annual Meeting
First Author: June Evelyn Jeon
2023 ASCO Annual Meeting
First Author: Jiaqi Liu
2023 ASCO Annual Meeting
First Author: Martina Pagliuca